These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31903932)

  • 1. [Developability assessment].
    Dumas J; Huille S; Prades C
    Med Sci (Paris); 2019 Dec; 35(12):1163-1170. PubMed ID: 31903932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Developability assessment with case studies highlighting the decision taking].
    Dumas J; Sévérac A; Lemoine C; Huille S; Rak A; Prades C
    Med Sci (Paris); 2019 Dec; 35(12):1171-1174. PubMed ID: 31903933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies.
    Gibbs WW
    Sci Am; 2005 Aug; 293(2):78-83. PubMed ID: 16053141
    [No Abstract]   [Full Text] [Related]  

  • 6. Biosimilars: An Approach to some Current Worldwide Regulation Frameworks.
    Esteban E; Bustos RH; García JC; Jáuregui E
    Curr Clin Pharmacol; 2019; 14(1):16-40. PubMed ID: 30360724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody fragments for controlled delivery of therapeutic agents.
    Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
    Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
    [No Abstract]   [Full Text] [Related]  

  • 8. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
    Farhat F; Torres A; Park W; de Lima Lopes G; Mudad R; Ikpeazu C; Abi Aad S
    Oncologist; 2018 Mar; 23(3):346-352. PubMed ID: 29284760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.
    Beck A; Reichert JM
    MAbs; 2013; 5(5):621-3. PubMed ID: 23924791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
    Calvo B; Zuñiga L
    Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
    Golay J; Introna M
    Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The advent of biosimilars: challenges and risks.
    Müller R; Renner C; Gabay C; Cassata G; Lohri A; Hasler P
    Swiss Med Wkly; 2014; 144():w13980. PubMed ID: 24984255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First biosimilar drug set to enter US market.
    Ledford H
    Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody Engineering & Design 2010. 24-25 February 2010, Frankfurt, Germany.
    Beck A
    IDrugs; 2010 May; 13(5):295-9. PubMed ID: 20432182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MI-mAbs, pre-industrial demonstrator supported by PIA for the early validation of therapeutic targets using monoclonal antibodies].
    Romagné F
    Med Sci (Paris); 2019 Dec; 35(12):1202-1203. PubMed ID: 31903940
    [No Abstract]   [Full Text] [Related]  

  • 18. A Streamlined Bioanalytical Approach to Select a Compatible Primary Container System Early in Drug Development: A Toolbox for the Biopharmaceutical Industry.
    Singh R; Waxman L
    J Pharm Sci; 2020 Jan; 109(1):206-210. PubMed ID: 31545968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.
    De Santis R
    MAbs; 2020; 12(1):1725346. PubMed ID: 32054397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The US Biosimilar Market: Stunted Growth and Possible Reforms.
    Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
    Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.